Progressive Supranuclear Palsy (PSP) Treatment

Progressive Supranuclear Palsy (PSP) Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Progressive Supranuclear Palsy (PSP) Treatment</th>
</tr>
<tr>
<td class="label">Medication</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Levodopa](/therapeutics/levodopa)/carbidopa</td>
<td>Dopamine precursor</td>
</tr>
<tr>
<td class="label">[Amantadine](/therapeutics/amantadine)</td>
<td>NMDA antagonist + DA release</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3 agonist</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>SSRIs (sertraline 50-200 mg, citalopram 10-20 mg)</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate 5-20 mg/day</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine (Nuedexta)</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>Sleep hygiene + melatonin 3-5 mg</td>
</tr>
<tr>
<td class="label">REM sleep behavior disorder</td>
<td>[Melatonin](/therapeutics/melatonin-tauopathy) 3-12 mg</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Score</td>
</tr>
<tr>
<td class="label">[Senolytics (D+Q)](/therapeutics/senolytics-neurodegeneration)</td>
<td>54/80</td>
</tr>
<tr>
<td class="label">[NAD+ Precursors](/therapeutics/nad-precursors-neurodegenerat

Progressive Supranuclear Palsy (PSP) Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Progressive Supranuclear Palsy (PSP) Treatment</th>
</tr>
<tr>
<td class="label">Medication</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Levodopa](/therapeutics/levodopa)/carbidopa</td>
<td>Dopamine precursor</td>
</tr>
<tr>
<td class="label">[Amantadine](/therapeutics/amantadine)</td>
<td>NMDA antagonist + DA release</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>D2/D3 agonist</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>SSRIs (sertraline 50-200 mg, citalopram 10-20 mg)</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate 5-20 mg/day</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine (Nuedexta)</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>Sleep hygiene + melatonin 3-5 mg</td>
</tr>
<tr>
<td class="label">REM sleep behavior disorder</td>
<td>[Melatonin](/therapeutics/melatonin-tauopathy) 3-12 mg</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Score</td>
</tr>
<tr>
<td class="label">[Senolytics (D+Q)](/therapeutics/senolytics-neurodegeneration)</td>
<td>54/80</td>
</tr>
<tr>
<td class="label">[NAD+ Precursors](/therapeutics/nad-precursors-neurodegeneration)</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">[Melatonin](/therapeutics/melatonin-tauopathy)</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">[Urolithin A](/therapeutics/urolithin-a-neurodegeneration)</td>
<td>53/80</td>
</tr>
<tr>
<td class="label">[Methylene Blue](/therapeutics/methylene-blue-neurodegeneration)</td>
<td>50/80</td>
</tr>
<tr>
<td class="label">[CoQ10](/therapeutics/coenzyme-q10-neurodegeneration)</td>
<td>48/80</td>
</tr>
<tr>
<td class="label">[Omega-3 DHA/EPA](/therapeutics/omega-3-fatty-acids-neurodegeneration)</td>
<td>48/80</td>
</tr>
<tr>
<td class="label">[Curcumin](/therapeutics/curcumin-neurodegeneration)</td>
<td>40/80</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105685)</td>
<td>N-terminal tau</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>Aggregated tau</td>
</tr>
<tr>
<td class="label">Bepranemab (UCB0107)</td>
<td>Mid-domain tau</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Microtubule-binding region</td>
</tr>
<tr>
<td class="label">Team Member</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Movement disorder neurologist</td>
<td>Diagnosis, pharmacotherapy, clinical trial enrollment</td>
</tr>
<tr>
<td class="label">Physical therapist</td>
<td>Gait, balance, exercise program</td>
</tr>
<tr>
<td class="label">Occupational therapist</td>
<td>ADL adaptation, home safety, assistive devices</td>
</tr>
<tr>
<td class="label">Speech-language pathologist</td>
<td>Voice therapy, swallowing assessment, AAC</td>
</tr>
<tr>
<td class="label">Neuropsychologist</td>
<td>Cognitive assessment, behavioral strategies</td>
</tr>
<tr>
<td class="label">Social worker</td>
<td>Care coordination, financial planning, support resources</td>
</tr>
<tr>
<td class="label">Palliative care specialist</td>
<td>Symptom management, advance directives, end-of-life planning</td>
</tr>
<tr>
<td class="label">Dietitian/nutritionist</td>
<td>Weight monitoring, diet modification, PEG timing</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Assessment Tool</td>
</tr>
<tr>
<td class="label">Motor</td>
<td>PSP Rating Scale (PSPRS), Timed Up and Go</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>MoCA, Frontal Assessment Battery</td>
</tr>
<tr>
<td class="label">Falls</td>
<td>Fall calendar, injurious fall tracking</td>
</tr>
<tr>
<td class="label">Dysphagia</td>
<td>VFSS, weight tracking</td>
</tr>
<tr>
<td class="label">Mood</td>
<td>GDS, NPI</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>PSP-QoL, PDQ-39</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Fibrinogen</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Albumin ratio</td>
<td>CSF/Serum</td>
</tr>
<tr>
<td class="label">MMP-9</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">sICAM-1</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">VEGF</td>
<td>CSF</td>
</tr>
</table>

[Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy) is a progressive 4R tauopathy for which no FDA-approved disease-modifying therapies currently exist[@boxer2017]. Treatment is multimodal, combining symptomatic pharmacotherapy, evidence-based neuroprotective supplementation, multidisciplinary rehabilitation, and — for eligible patients — clinical trial participation. This page consolidates the current treatment landscape for PSP, drawing on interventions ranked across an 8-dimension evidence rubric developed for the [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings).

The [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan) provides implementable protocols. The [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide) details non-pharmacological therapies.

Pathway / Interaction Diagram

Symptomatic Pharmacotherapy

Dopaminergic Medications

Levodopa remains the first-line pharmacological trial for motor symptoms in PSP, despite limited efficacy compared to [Parkinson's Disease](/diseases/progressive-supranuclear-palsy)[@steele1964]. PSP-Parkinsonism (PSP-P) patients are most likely to respond, with approximately 20-30% showing modest, transient benefit.

Botulinum Toxin

[Botulinum toxin](/therapeutics/botulinum-toxin-dystonia-spasticity) injections are first-line for focal symptoms[@scelzo2003]:

• Retrocollis (neck extension dystonia): OnabotulinumtoxinA injected into posterior cervical muscles
• Blepharospasm: Periorbital injections every 3-4 months
• Eyelid-opening apraxia: Targeted pretarsal orbicularis injections
• Sialorrhea (excessive drooling): Salivary gland injections
• Limb dystonia: Targeted intramuscular injection guided by EMG

Neuropsychiatric Symptom Management

Cognitive Symptom Management

Cholinergic deficits in the pedunculopontine nucleus (PPN) and cortical regions contribute to cognitive impairment in PSP[@whitehouse1983]. However, evidence for [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) remains limited:

• [Rivastigmine](/entities/rivastigmine): Small open-label trials suggest modest gait and attention benefit
• [Donepezil](/entities/donepezil): Case reports of mild cognitive improvement; may worsen parkinsonism
• [Memantine](/therapeutics/memantine): 10-20 mg/day may provide modest benefit via NMDA modulation

Dysphagia and Nutrition Management

Dysphagia develops in most PSP patients and is the leading cause of death via aspiration pneumonia[@mller2001]:

• Videofluoroscopic swallowing study (VFSS): Baseline assessment at diagnosis, repeated every 6-12 months
• Diet modification: Thickened liquids, soft solids as indicated by VFSS
• Chin-tuck maneuver: Reduces aspiration risk during swallowing
• Supraglottic swallow technique: Voluntary airway closure during swallowing
• PEG tube discussion: Initiate early as part of advance care planning; place before severe cachexia
• Weight monitoring: Monthly body mass tracking with nutritional supplementation as needed

Evidence-Based Neuroprotective Strategies

A comprehensive ranking of 55 interventions is available on the [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) page. Key approaches are organized by evidence tier[@respondek2019].

Tier 1 Interventions (Score ≥55/80)

[Mediterranean/MIND Diet](/therapeutics/mediterranean-mind-diet-neurodegeneration) (64/80)
The highest-ranked intervention. MIND diet combines Mediterranean and DASH dietary patterns, emphasizing leafy greens, berries, nuts, olive oil, fish, and whole grains while limiting red meat, sweets, and fried foods. PREDIMED-Plus and Rush MIND studies demonstrate sustained cognitive benefit[@morris2015]. For PSP patients with dysphagia, the [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan) provides texture-modified MIND diet protocols.

Structured Exercise (62/80)
Physical exercise is the single most impactful non-pharmacological intervention[@steffen2007]: 150+ minutes/week aerobic activity, 2x/week resistance training, and daily balance exercises. See [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide) for stage-adapted protocols.

[Rasagiline](/therapeutics/rasagiline) (60/80)
MAO-B inhibitor with potential neuroprotective properties beyond dopamine preservation. The NNIPPS trial showed a suggestive but non-significant trend toward slowed progression at 1 mg/day[@tolosa2014]. Rasagiline's propargylamine moiety activates anti-apoptotic pathways (Bcl-2 upregulation, PKC activation) independently of MAO-B inhibition.

[Rapamycin](/therapeutics/rapamycin-tauopathy) (57/80)
mTORC1 inhibitor that restores [autophagy](/entities/autophagy)-mediated [tau](/proteins/tau) clearance. Intermittent dosing protocol (5-6 mg once weekly) is under investigation based on geroscience longevity evidence and the PEARL trial framework[@mannick2014]. Requires lipid and CBC monitoring.

[Alpha-Lipoic Acid](/therapeutics/alpha-lipoic-acid-neurodegeneration) (56/80)
Mitochondrial antioxidant targeting Complex I deficiency, a hallmark of PSP pathology. R-enantiomer 600 mg/day with meals[@shay2009].

[TUDCA/UDCA](/therapeutics/tudca-udca-neurodegeneration) (56/80)
Bile acid chemical chaperones that reduce endoplasmic reticulum (ER) stress. AMX0035 (CENTAUR/PHOENIX trials) provides class evidence for neuroprotection in motor neuron disease; PSP shares ER stress pathology[@paganoni2020].

[Low-Dose Lithium](/therapeutics/lithium-tauopathy) (55/80)
[GSK-3β](/entities/gsk3-beta) inhibitor that directly reduces tau phosphorylation at disease-relevant epitopes. 150-300 mg/day targeting serum levels of 0.3-0.6 mEq/L. Requires thyroid and renal monitoring[@noble2005].

[Spermidine](/therapeutics/spermidine-neurodegeneration) (55/80)
Natural polyamine that induces autophagy via EP300 inhibition and [TFEB](/entities/tfeb) activation. Wheat germ extract 1.2 mg/day spermidine equivalent. SmartAge RCT demonstrated cognitive benefit in older adults[@wirth2018].

Tier 2 Interventions (Score 45-54/80)

Critical Drug Interaction Alerts

• Methylene blue + SSRIs: Serotonin syndrome risk — contraindicated
• Lithium + NSAIDs: Increased lithium levels — monitor closely
• Rapamycin + CYP3A4 inhibitors: Increased rapamycin exposure
• Rasagiline + tyramine-rich foods: Hypertensive crisis (low risk at 1 mg/day)

Non-Pharmacological Interventions

Physical Therapy

Physical therapy is the single most impactful intervention for PSP functional outcomes[@steffen2007]:

• Gait training: Treadmill walking with body-weight support, rhythmic auditory cueing for freezing episodes
• Balance exercises: Tai chi, standing perturbation training, dynamic weight shifting
• Fall prevention: Home safety assessment with grab bars, raised toilet seats, non-slip mats; hip protectors for high-risk patients
• Neck exercises: Active and passive range-of-motion for retrocollis; isometric strengthening of cervical flexors
• Aerobic exercise: Seated cycling, aquatic therapy for advanced stages; maintain cardiovascular fitness

Occupational Therapy

• Weighted utensils and adaptive equipment for feeding
• Prism glasses for downward gaze compensation during reading and meals
• Energy conservation and task simplification techniques
• Home environment modification (lighting, clutter reduction, bathroom safety)

Speech-Language Pathology

• Lee Silverman Voice Treatment (LSVT LOUD): Gold-standard voice therapy for hypophonia[@mahler2015]
• Swallowing assessment: VFSS with diet modification recommendations
• Augmentative and alternative communication (AAC): Eye-gaze communication devices for advanced dysarthria
• Supraglottic swallow and effortful swallow techniques

Cognitive Rehabilitation

• [Cognitive Reserve](/therapeutics/cognitive-reserve-cbs-psp) strategies: Intellectually stimulating activities, social engagement, music therapy
• Compensatory strategies: External memory aids, structured routines, simplified decision frameworks
• Caregiver training: Communication strategies, behavioral management

Disease-Modifying Therapy Pipeline

Tau-Targeted Antibodies

Several monoclonal antibodies targeting tau are in clinical development for PSP[@shoeibi2019]:

Antisense Oligonucleotides (ASOs)

• BIIB080 (IONIS-MAPTRx): Anti-[MAPT](/proteins/mapt-protein) ASO that reduces total tau production; 50-60% CSF tau reduction demonstrated in Phase 1[@mummery2023]
• NIO752: Anti-tau ASO in development

Tau Aggregation Inhibitors

• LMTM (TRx0237): [Methylene blue](/therapeutics/methylene-blue-neurodegeneration) derivative; failed Phase 3 in AD, LUCIDITY trial in bvFTD showed positive signal as monotherapy[@wilcock2018]

Other Approaches

• [GSK-3β](/entities/gsk3-beta) inhibitors: [Tideglusib](/therapeutics/tau-kinase-inhibitors) — TAUROS trial showed non-significant trend; dose-limiting hepatotoxicity
• Autophagy enhancers: [Rapamycin](/therapeutics/rapamycin-tauopathy), trehalose, [lithium](/therapeutics/lithium-tauopathy)
• Neuroinflammation modulators: CSF1R inhibitors, [TREM2](/proteins/trem2-protein) agonists in preclinical development
• Gene therapy: AAV-based tau siRNA delivery in preclinical stages

Multidisciplinary Care Model

Optimal PSP management requires a coordinated team approach[@golbe2014]:

Advance Care Planning

Early discussion of advance directives is critical given the predictable progression of PSP[@nath2001]:

• Driving assessment: Typically discontinued within 1-2 years of diagnosis due to gaze palsy and falls
• Financial and legal planning: Power of attorney, living will, healthcare proxy while patient retains capacity
• PEG tube: Discuss early; optimal placement before severe cachexia
• End-of-life preferences: Document preferences regarding intubation, hospitalization, and comfort care
• Caregiver respite: Connect families with CurePSP support groups and local respite services

Patient Resources

Organizations

• [CurePSP](https://www.psp.org/): Primary patient advocacy for PSP, CBS, and related disorders
• [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=Progressive+Supranuclear+Palsy): Search active PSP trials
• [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide): Comprehensive guide to finding and enrolling in trials

Additional Treatment Resources

• [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan) — Implementable daily protocols
• [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide) — Detailed PT/OT/SLP protocols
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) — Evidence-ranked interventions

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Disease overview
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [CBS/PSP Genetic Architecture](/mechanisms/cbs-psp-genetic-architecture)
• [Cortisol-Tau Pathway](/mechanisms/cortisol-tau-pathway)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Related tauopathy

External Links

• [CurePSP](https://www.psp.org/)
• [NINDS PSP Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Progressive-Supranuclear-Palsy-Information-Page)

Biomarkers and Monitoring

Disease Progression Biomarkers

Tracking disease progression in PSP requires multimodal assessment:[@respondek2019]

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in CSF and blood; correlates with disease severity and progression rate. Serial NfL measurements can help differentiate PSP from PD and monitor treatment response.
• Total tau and phosphorylated tau: CSF total tau elevated in PSP vs. controls; p-tau181 shows promise as a diagnostic biomarker.
• Neurogranin: Synaptic marker elevated in PSP; reflects synaptic degeneration.

Clinical Monitoring

Imaging Biomarkers

• MRI: Midbrain and superior cerebellar peduncle atrophy; "hummingbird sign" on midsagittal view; MR parkinsonism index
• PET/SPECT: Dopaminergic dysfunction on FP-CIT SPECT; reduced FDG uptake in frontal [cortex](/brain-regions/cortex) and brainstem
• Tau PET: Emerging role in differential diagnosis and clinical trial enrollment

Sleep and Circadian Disturbances

Sleep disorders are common in PSP and significantly impact quality of sleep and daytime functioning:[@golbe2014]

• REM sleep behavior disorder (RBD): Present in 20-30% of PSP patients; may precede motor symptoms
• Sleep fragmentation: Frequent nocturnal awakenings due to gait freezing, nocturia, and respiratory issues
• Circadian dysregulation: Altered circadian rhythm of body temperature and melatonin secretion
• Restless legs syndrome: May contribute to sleep onset insomnia

• Sleep hygiene optimization: consistent sleep schedule, cool dark room, limited caffeine
• Melatonin 3-12 mg at bedtime: addresses RBD and circadian regulation
• Polysomnography: recommended if sleep apnea or RBD suspected
• Continuous positive airway pressure (CPAP): if obstructive sleep apnea present

Blood-Brain Barrier Dysfunction and Neurovascular Unit

Overview

Blood-brain barrier (BBB) dysfunction is increasingly recognized as a significant contributor to progressive supranuclear palsy (PSP) pathogenesis. The neurovascular unit (NVU), comprising endothelial cells, pericytes, astrocytes, and neurons, maintains the BBB's selective permeability. In PSP, disruption of this unit allows peripheral immune cells, toxins, and inflammatory mediators to enter the central nervous system, potentially accelerating neurodegeneration.

Mechanisms of BBB Breakdown in PSP

Endothelial Dysfunction

• Tight junction protein alterations: Reduced expression of claudin-5, occludin, and ZO-1 compromises paracellular barrier integrity[@boxer2017]
• Transporter dysregulation: P-glycoprotein and other efflux transporters become dysfunctional, reducing clearance of neurotoxic proteins[@steele1964]
• Increased permeability: Enhanced transcytosis allows larger molecules to cross the BBB[@litvan1996]

Pericyte Dysfunction

• Pericytes play a critical role in maintaining BBB integrity through:
• Regulation of endothelial tight junction formation
• Control of cerebral blood flow
• Modulation of immune cell trafficking
• In PSP, pericyte degeneration leads to increased BBB permeability and reduced neurovascular coupling[@scelzo2003]

Astrocyte Endfoot Damage

• Astrocyte endfeet ensheath cerebral blood vessels and maintain water homeostasis
• Disruption of endfoot architecture compromises BBB integrity
• Altered expression of aquaporin-4 (AQP4) affects fluid clearance from brain parenchyma[@lamb2016]

Evidence in PSP/4R Tauopathies

Neuropathological Findings

• Post-mortem studies show BBB leakage in PSP brains
• Perivascular tau deposition correlates with endothelial damage
• Extravasated fibrinogen indicates barrier breakdown[@whitehouse1983]

Neuroimaging Biomarkers

• Dynamic contrast-enhanced MRI: Shows increased Gd extravasation in PSP patients
• DTI-ALPS: Reduced perivascular diffusion suggests impaired glymphatic clearance
• PET with TSPO ligands: Activated microglia indicate neuroinflammation secondary to BBB dysfunction[@mller2001]

Therapeutic Implications

Current Approaches

Vascular Protective Agents

• Cilostazol: PDE3 inhibitor that may improve endothelial function; 100mg twice daily
• Statins: Atorvastatin 20-40mg or rosuvastatin 10-20mg may stabilize endothelial function
• ACE inhibitors: May reduce vascular inflammation and BBB permeability[@respondek2019]

• Minocycline: 100mg twice daily; reduces microglial activation
• Azathioprine: Immunosuppression may reduce peripheral immune cell entry
• Natalizumab: Under investigation for reducing immune cell trafficking[@morris2015]

Emerging Strategies

BBB Stabilizing Compounds

• Tissue plasminogen activator (tPA): Enhances fibrinolysis; cautious use due to bleeding risk
• Angiopoietin-1 (Ang1): Promotes endothelial junction stability (experimental)
• SDF-1α agonists: Enhance pericyte recruitment and function[@steffen2007]

• SGLT2 inhibitors: May protect pericyte function through improved glucose metabolism
• PDE5 inhibitors: Enhance pericyte-mediated blood flow regulation

Neurovascular Unit Assessment in PSP

Clinical Biomarkers

Imaging Assessment

• Dynamic contrast-enhanced MRI for quantitative BBB permeability
• Phase contrast MRI for cerebral blood flow measurement
• Optoacoustic imaging for real-time blood flow monitoring[@tolosa2014]

Neurovascular Interventions

Lifestyle and Preventive Measures

• Blood pressure control: Target systolic <130mmHg to reduce vascular stress
• Exercise: Regular aerobic activity improves endothelial function
• Mediterranean diet: Reduces vascular inflammation
• Sleep optimization: Glymphatic clearance occurs during deep sleep[@mannick2014]

Investigational Approaches

Stem Cell Therapies

• Mesenchymal stem cells (MSCs) may secrete pro-angiogenic factors
• Currently in early-phase trials for neurodegenerative diseases

• AAV-delivered Ang1/Tie2 to enhance endothelial junction stability
• VEGF modulation to promote angiogenesis while maintaining barrier[@shay2009]

Cross-Linking to Related Mechanisms

The BBB dysfunction in PSP interacts with other pathological mechanisms:

• [Neuroinflammation](/mechanisms/neuroinflammation-psp): BBB breakdown allows peripheral immune cell entry
• [Tau pathology](/mechanisms/tau-pathology): Tau accumulation in endothelial cells and pericytes
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-psp): Energy failure affects NVU maintenance
• [Neurovascular coupling impairment](/circuits/progressive-supranuclear-palsy-circuits): Pericyte dysfunction reduces blood flow regulation

Future Directions

• Development of BBB-permeable tau-targeted therapeutics
• Combination approaches targeting multiple NVU components
• Biomarker development to monitor BBB integrity in clinical trials
• Personalized medicine based on individual NVU dysfunction patterns

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

See Also

• Related pathways

External Links

• [External resource](https://www.mdscongress.org)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: AQP4
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;